Nivolumab for Resected Stage III or IV Melanoma at 9 Years

The 9-year final data support a sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906; Eudra-CT number, 2014-002351-26.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-10-18
DOI
https://doi.org/10.1056/nejmoa2504966
Citations
9
Primary Topic
Cutaneous Melanoma Detection and Management
Type
article
Field-Weighted Citation Impact
9.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Michele Del Vecchio, Marcus O. Butler, Ana Arance, Luis de la Cruz‐Merino et al.
9 citations
New England Journal of Medicine
Cutaneous Melanoma Detection and Management
9.41
article

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Michele Del Vecchio, Marcus O. Butler, Ana Arance, Luis de la Cruz‐Merino, Andrew F. Hill, Leslie A. Fecher, Michael Schenker, Devanand Joseph, Paolo A. Ascierto, Barbara Merelli, Melanie Pe Benito, Petr Arenberger, Paul Craig Nathan, Caroline Gaudy‐Marqueste, Charles Lance Cowey, Jacopo Pigozzo, Nikhil I. Khushalani, Iván Márquez‐Rodas, Paola Queirolo, Stéphane Dalle, James Larkin, Margarita Askelson, Michael Millward, Raheela Soomro, Oleg Gligich, Helen J Gogas, Victoria Atkinson, Anna Maria Di Giacomo, Dhanrajsinh Rathod
article en
9 citations

Abstract

The 9-year final data support a sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906; Eudra-CT number, 2014-002351-26.).

New England Journal of MedicineVol. 394(4)
University of Siena (IT), The University of Queensland (AU), The University of Western Australia (AU), National and Kapodistrian University of Athens (GR), Charles University (CZ), Aix-Marseille Université (FR), University of Michigan (US), Texas Oncology (US), Princess Alexandra Hospital (AU), Sir Charles Gairdner Hospital (AU), Princess Margaret Cancer Centre (CA), University of Medicine and Pharmacy of Craiova (RO), Hospital General Universitario Gregorio Marañón (ES), Moffitt Cancer Center (US), Assistance Publique Hôpitaux de Marseille (FR), Hospital Universitario Virgen Macarena (ES), Bristol-Myers Squibb (United States) (US), Hospices Civils de Lyon (FR), Ospedale Papa Giovanni XXIII (IT), Mount Vernon Cancer Centre (GB), Istituto Oncologico Veneto (IT), Trans Tasman Radiation Oncology Group (AU), Royal Marsden Hospital (GB), Gallipoli Medical Research Foundation (AU), Instituto de Biomedicina de Sevilla (ES), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), University Hospital Kralovske Vinohrady (CZ), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), European Institute of Oncology (IT), Universidad de Sevilla (ES), University of Craiova (RO)
Openalex Percentile: Top 2%
Cutaneous Melanoma Detection and Management
9.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.